NEUROGENE INC (NGNE) Stock Fundamental Analysis

NASDAQ:NGNE • US64135M1053

19.67 USD
+0.77 (+4.07%)
Last: Feb 25, 2026, 01:16 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to NGNE. NGNE was compared to 521 industry peers in the Biotechnology industry. While NGNE seems to be doing ok healthwise, there are quite some concerns on its profitability. NGNE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year NGNE has reported negative net income.
  • In the past year NGNE has reported a negative cash flow from operations.
  • In the past 5 years NGNE always reported negative net income.
  • NGNE had a negative operating cash flow in each of the past 5 years.
NGNE Yearly Net Income VS EBIT VS OCF VS FCFNGNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • NGNE's Return On Assets of -26.11% is fine compared to the rest of the industry. NGNE outperforms 70.25% of its industry peers.
  • NGNE has a Return On Equity of -28.30%. This is in the better half of the industry: NGNE outperforms 77.35% of its industry peers.
Industry RankSector Rank
ROA -26.11%
ROE -28.3%
ROIC N/A
ROA(3y)-29.45%
ROA(5y)-28.26%
ROE(3y)-34.92%
ROE(5y)-32.93%
ROIC(3y)N/A
ROIC(5y)N/A
NGNE Yearly ROA, ROE, ROICNGNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NGNE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NGNE Yearly Profit, Operating, Gross MarginsNGNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • NGNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NGNE has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, NGNE has more shares outstanding
  • Compared to 1 year ago, NGNE has an improved debt to assets ratio.
NGNE Yearly Shares OutstandingNGNE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
NGNE Yearly Total Debt VS Total AssetsNGNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 6.41 indicates that NGNE is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.41, NGNE is in the better half of the industry, outperforming 75.05% of the companies in the same industry.
  • A Debt/Equity ratio of 0.00 indicates that NGNE is not too dependend on debt financing.
  • NGNE has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.41
ROIC/WACCN/A
WACC8.67%
NGNE Yearly LT Debt VS Equity VS FCFNGNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 18.39 indicates that NGNE has no problem at all paying its short term obligations.
  • NGNE has a Current ratio of 18.39. This is amongst the best in the industry. NGNE outperforms 95.01% of its industry peers.
  • A Quick Ratio of 18.39 indicates that NGNE has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 18.39, NGNE belongs to the top of the industry, outperforming 95.01% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 18.39
Quick Ratio 18.39
NGNE Yearly Current Assets VS Current LiabilitesNGNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 14.20% over the past year.
EPS 1Y (TTM)14.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, NGNE will show a very strong growth in Earnings Per Share. The EPS will grow by 27.62% on average per year.
  • The Revenue is expected to grow by 185.19% on average over the next years. This is a very strong growth
EPS Next Y-0.23%
EPS Next 2Y-11.54%
EPS Next 3Y-12.73%
EPS Next 5Y27.62%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y185.19%

3.3 Evolution

NGNE Yearly Revenue VS EstimatesNGNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2024 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
NGNE Yearly EPS VS EstimatesNGNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 2031 2032 2033 0 -20 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NGNE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NGNE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NGNE Price Earnings VS Forward Price EarningsNGNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NGNE Per share dataNGNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

  • NGNE's earnings are expected to decrease with -12.73% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.54%
EPS Next 3Y-12.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • NGNE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEUROGENE INC

NASDAQ:NGNE (2/25/2026, 1:16:35 PM)

19.67

+0.77 (+4.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-23
Inst Owners104.75%
Inst Owner Change7.51%
Ins Owners8.5%
Ins Owner Change0%
Market Cap304.69M
Revenue(TTM)925.00K
Net Income(TTM)-75.14M
Analysts86.67
Price Target60.18 (205.95%)
Short Float %25.34%
Short Ratio22.88
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.75%
Min EPS beat(2)11.15%
Max EPS beat(2)22.35%
EPS beat(4)4
Avg EPS beat(4)12.01%
Min EPS beat(4)0.42%
Max EPS beat(4)22.35%
EPS beat(8)6
Avg EPS beat(8)4.78%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.46%
EPS NY rev (1m)0%
EPS NY rev (3m)11.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 329.39
P/FCF N/A
P/OCF N/A
P/B 1.15
P/tB 1.15
EV/EBITDA N/A
EPS(TTM)-4.11
EYN/A
EPS(NY)-5.31
Fwd EYN/A
FCF(TTM)-5.06
FCFYN/A
OCF(TTM)-4.99
OCFYN/A
SpS0.06
BVpS17.14
TBVpS17.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.11%
ROE -28.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.45%
ROA(5y)-28.26%
ROE(3y)-34.92%
ROE(5y)-32.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.37%
Cap/Sales 126.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.39
Quick Ratio 18.39
Altman-Z 6.41
F-Score3
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)35.41%
Cap/Depr(5y)127.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.81%
EPS Next Y-0.23%
EPS Next 2Y-11.54%
EPS Next 3Y-12.73%
EPS Next 5Y27.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y185.19%
EBIT growth 1Y-48.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-138.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-139.25%
OCF growth 3YN/A
OCF growth 5YN/A

NEUROGENE INC / NGNE FAQ

What is the fundamental rating for NGNE stock?

ChartMill assigns a fundamental rating of 3 / 10 to NGNE.


What is the valuation status of NEUROGENE INC (NGNE) stock?

ChartMill assigns a valuation rating of 0 / 10 to NEUROGENE INC (NGNE). This can be considered as Overvalued.


Can you provide the profitability details for NEUROGENE INC?

NEUROGENE INC (NGNE) has a profitability rating of 1 / 10.


Can you provide the financial health for NGNE stock?

The financial health rating of NEUROGENE INC (NGNE) is 6 / 10.